2. Natural Products
  3. Disease Research Fields Plants Terpenoids
  4. Araliaceae Cancer Triterpenes
  5. Panax ginseng C. A. Meyer
  6. (20R)-Ginsenoside Rg3

(20R)-Ginsenoside Rg3  (Synonyms: (20R)-Propanaxadiol; R-ginsenoside Rg3)

Cat. No.: HY-N1376 Purity: 99.84%
SDS COA Handling Instructions

Molarity Calculator

(20R)-ginsenoside Rg3 ((20R)-Propanaxadiol), one of the active compounds present in ginseng root, inhibits angiogenesis, and has anti-carcinogenic and antimetastatic effects.

For research use only. We do not sell to patients.

(20R)-Ginsenoside Rg3 Chemical Structure

(20R)-Ginsenoside Rg3 Chemical Structure

CAS No. : 38243-03-7

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
5 mg USD 32 In-stock
10 mg USD 50 In-stock
50 mg USD 150 In-stock
100 mg USD 220 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of (20R)-Ginsenoside Rg3:

(20R)-Ginsenoside Rg3 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

(20R)-ginsenoside Rg3 ((20R)-Propanaxadiol), one of the active compounds present in ginseng root, inhibits angiogenesis, and has anti-carcinogenic and antimetastatic effects[1].

Cellular Effect
Cell Line Type Value Description References
A549 IC50
55.36 μg/mL
Compound: 20S-Rg3
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
[PMID: 24321343]
HepG2 IC50
54 μg/mL
Compound: Rg3
Cytotoxicity against human HepG2 cells after 24 hrs by CCK-8 assay
Cytotoxicity against human HepG2 cells after 24 hrs by CCK-8 assay
[PMID: 25227718]
In Vitro

(20R)-ginsenoside Rg3 inhibits the proliferation of human umbilical vein endothelial cells (HUVEC) with an IC50 of 10 nM[1].
(20R)-ginsenoside Rg3 also dose dependently suppresses the capillary tube formation of HUVEC on the Matrigel in the presence or absence of 20 ng/mL VEGF[1].
(20R)-ginsenoside Rg3 significantly attenuates the VEGF-induced chemoinvasion of HUVEC and ex vivo microvascular sprouting in rat aortic ring assay[1].
(20R)-ginsenoside Rg3 (150 and 600 nM) remarkably abolishes the basic fibroblast growth factor (bFGF)-induced angiogenesis in an in vivo Matrigel plug assay[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(20R)-Ginsenoside Rg3 Related Antibodies

Cell Viability Assay[1]

Cell Line: HUVEC
Concentration: 1 nM, 10 nM, 100 nM, 1000 nM
Incubation Time: 48 h
Result: Inhibited the proliferation of HUVEC.
In Vivo

(20R)-ginsenoside Rg3 (0.05-0.5 mg/kg; intranasal administration; for 2 weeks) shows anti-fatigue effect in mice by intranasally administration[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Kunming mice weighing 18-22 g[2]
Dosage: 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg (5 μL each nostril)
Administration: Intranasal administration; for 2 weeks
Result: Significantly prolonged the weight-loaded swimming time, and also increased the hepatic glycogen levels.
Molecular Weight

785.01

Formula

C42H72O13
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O[C@@H]([C@@H]([C@@H](CO)O1)O)[C@@H](O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)[C@@H]1O[C@H]3CC[C@]4(C)[C@@]5([H])C[C@@H](O)[C@]6([H])[C@@H]([C@](C)(O)CC/C=C(C)\C)CC[C@](C)6[C@@](C)5CCC4C3(C)C
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 25 mg/mL (31.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.2739 mL 6.3693 mL 12.7387 mL
5 mM 0.2548 mL 1.2739 mL 2.5477 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.84%

SDS (393 KB)

COA (255 KB) HNMR (137 KB) RP-HPLC (241 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.2739 mL 6.3693 mL 12.7387 mL 31.8467 mL
5 mM 0.2548 mL 1.2739 mL 2.5477 mL 6.3693 mL
10 mM 0.1274 mL 0.6369 mL 1.2739 mL 3.1847 mL
15 mM 0.0849 mL 0.4246 mL 0.8492 mL 2.1231 mL
20 mM 0.0637 mL 0.3185 mL 0.6369 mL 1.5923 mL
25 mM 0.0510 mL 0.2548 mL 0.5095 mL 1.2739 mL
30 mM 0.0425 mL 0.2123 mL 0.4246 mL 1.0616 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

(20R)-Ginsenoside Rg3 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(20R)-Ginsenoside Rg338243-03-7(20R)-Propanaxadiol R-ginsenoside Rg3OthersInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
(20R)-Ginsenoside Rg3
Cat. No.:
HY-N1376
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.